AWH
Aspira Women's Health Inc. Common Stock
Delisted
AWH was delisted on the 16th of April, 2025.
About: Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
Employees: 66
Financial journalist opinion
Neutral
Accesswire
2 days ago
Aspira Women's Health Partners with Dorsata to Offer Access to 300+ Women's Health Practices, 1.5 Million + New Patients
Aspira and Dorsata Launch Clinical Workflow Tool for Adnexal Masses, Now Live for All Dorsata Clients, Adnexal Mass Evidence-Based Decision Support AUSTIN, TX AND WASHINGTON, DC / ACCESS Newswire / June 17, 2025 / Aspira Women's Health Inc. a bio-analytical-based women's health company focused on gynecologic disease diagnostics, and Dorsata, a leading clinical decision-support and provider workflow platform for women's health, announced today the official launch of a new adnexal mass clinical decision support module in partnership with Dorsata, a leading women's health electronic health record software solutions company. Dorsata's platform is currently used by more than 700 women's health providers across over 300 practice sites in 20 states, helping clinicians standardize care delivery and improve outcomes through guided clinical workflows and real-time decision support for over 1.5 million patients each year.
Neutral
Accesswire
1 week ago
Aspira Women's Health Provides Update on ARPA-H Sprint Program Partnership to Advance Women's Health
AUSTIN, TX AND WASHINGTON, DC / ACCESS Newswire / June 11, 2025 / Aspira Women's Health Inc., ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announces an update from the Advanced Research Projects Agency for Health's ( ARPA-H ) Sprint for Women's Health program initiative to address critical unmet needs in women's health. Aspira was originally awarded a $10 Million award through ARPA-H's Sprint for Women's Health to support the development of Aspira's ENDOinform test, a non-invasive blood draw-based multi-omics test utilizing protein and microRNA biomarkers, along with patient-specific data, to fuel a powerful, AI-powered algorithm to aid in the diagnosis of endometriosis in patients with symptoms of the disease.
Neutral
Accesswire
1 month ago
Aspira Announces First Quarter 2025 Financial Results and Provides Business Update
AUSTIN, TX / ACCESS Newswire / May 19, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three-month period ended March 31, 2025. The Company also reported early progress under its new leadership team.
Neutral
Accesswire
1 month ago
Aspira Successfully Completes Application to the OTCQB
AUSTIN, TX / ACCESS Newswire / May 7, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering the leading tools critical to gynecologic disease diagnostics and disease management, today announced it has successfully completed the process of transitioning to the OTCQB markets exchange. The Company begins trading on the OTCQB marketplace today, May 7, 2025.
Neutral
Accesswire
1 month ago
Aspira Reaches Another ARPA-H Milestone, Eligible to Receive Additional $1.5 Million in Second Quarter
Aspira Women's Health Submits the Third Milestone of ARPA-H $10 Million Award AUSTIN, TX / ACCESS Newswire / May 1, 2025 / Aspira Women's Health Inc. ("Aspira") (OTC PINK:AWHL), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful submission of its third development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. The third milestone focused heavily on additional analytical development steps.
Neutral
Accesswire
2 months ago
Aspira Women's Health Inc. to Begin Trading April 17th On OTC Under the Symbol "AWHL"
SHELTON, CT / ACCESS Newswire / April 17, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that at beginning of trading on April 17, 2025, the Company expects that its Common Stock will begin trading under its new symbol "AWHL" on markets operated by the OTC Markets Group, Inc. This symbol replaces the prior symbol "AWH" under which the Company previously traded. About Aspira Women's Health Inc. Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
Neutral
Accesswire
2 months ago
Aspira Women's Health Inc. Announces Receipt of Delisting Notification from Nasdaq
SHELTON, CT / ACCESS Newswire / April 16, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that on April 15, 2025, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's shares from Nasdaq due to the Company's failure to meet Nasdaq's continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market.
Neutral
Accesswire
2 months ago
Aspira Appoints Three New Directors, Executes $2.0 Million Equity Purchase Agreement
New Directors Bring Extensive Commercial Healthcare Relationships to Expand Business Development Opportunities. AUSTIN, TX / ACCESS Newswire / April 8, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of three new Directors to its Board of Directors.
Neutral
Accesswire
2 months ago
Aspira Receives $1.5 million Milestone Payment from the ARPA-H Sprint for Women's Health Award
The Company Successfully Reaches the Second Milestone of ARPA-H $10 Million Award AUSTIN, TX / ACCESS Newswire / March 31, 2025 / Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the second development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result of satisfying the second development milestone, Aspira received a $1.5 million cash payment under the terms of the related $10 million agreement.
Neutral
Accesswire
2 months ago
Aspira Women's Health Reports Fourth Quarter and Full Year 2024 Financial Results
Record 2024 OvaSuite revenue of $9.2 million and volume of 24,305 units sold AUSTIN, TX / ACCESS Newswire / March 27, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2024. Select financial results are as follows: Fourth Quarter 2024 and Recent Financial Highlights • Product revenue increased 9.5% to $2.3 million for the three months ended December 31, 2024, compared to $2.1 million for the same period in 2023.
Charts implemented using Lightweight Charts™